Soluble CXCL16 predicts long-term mortality in acute coronary syndromes

Circulation

Volumn 119, Issue 25, 2009, Pages 3181-3188

  Jansson, Anna M ^a   Aukrust, Pål ^d,e   Ueland, Thor ^d   Smith, Camilla ^d   Omland, Torbjørn ^e   Hartford, Marianne ^b,c   Caidahl, Kenneth ^a,b,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angina pectoris; Echocardiography; Myocardial infarction; Peptides, natriuretic B type; Prognosis; Proteins, C reactive

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CXCL16 CHEMOKINE; TROPONIN T; ALPHA CHEMOKINE; BIOLOGICAL MARKER; CXCL16 PROTEIN, HUMAN; SCAVENGER RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS; BLOOD; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SOLUBILITY; STATISTICS;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINES, CXC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, SCAVENGER; RISK FACTORS; SOLUBILITY; TROPONIN T;

EID: 67650767016     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.806877     Document Type: Article

References (24)

1. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, Gullestad L, Damas JK. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2008;28:1909-1919.
2. Schulz C, Schafer A, Stolla M, Kerstan S, Lorenz M, von Bruhl ML, Schiemann M, Bauersachs J, Gloe T, Busch DH, Gawaz M, Massberg S. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation. 2007;116:764-773.
3. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718-723.
4. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost. 2007; 97:748-754.
5. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Yonehara S, Kita T. Expression of scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) in human atheroma. Ann N Y Acad Sci. 2001;947:373-376.
6. Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Froland SS, Oie E, Gullestad L, Damas JK, Aukrust P. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res. 2008;79:195-203.
7. Wuttge DM, Zhou X, Sheikine Y, Wagsater D, Stemme V, Hedin U, Stemme S, Hansson GK, Sirsjo A. CXCL16/SR-PSOX is an interferongamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24:750-755.
8. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation. 2006; 114:583-590.
9. Sheikine Y, Bang CS, Nilsson L, Samnegard A, Hamsten A, Jonasson L, Eriksson P, Sirsjo A. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis. 2006; 188:462-466.
10. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol. 2007;49:442-449.
11. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost. 2007;97:694-703.
12. Perers E, Caidahl K, Herlitz J, Sjolin M, Karlson BW, Karlsson T, Hartford M. Spectrum of acute coronary syndromes: history and clinical presentation in relation to sex and age. Cardiology. 2004;102:67-76.
13. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918.
14. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007;49:1193-1202.
15. van Lieshout AW, Popa C, Meyer-Wentrup F, Lemmers HL, Stalenhoef AF, Adema GJ, van Riel PL, van Tits LJ, Radstake TR. Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. Biochem Biophys Res Commun. 2007;355:392-397.
16. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol. 2007;179:7166-7175.
17. Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci. 2008;99:1362-1369.
18. Galkina E, Harry BL, Ludwig A, Liehn EA, Sanders JM, Bruce A, Weber C, Ley K. CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation. 2007;116:1801-1811.
19. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T, Yonehara S. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. 2000; 275:40663-40666.
20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
21. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation. 2007;116:1052-1061.
22. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.
23. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003; 108:275-281.
24. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116.